资讯
Bayesian Health Sepsis Monitor Wins Medicare Add-on Payment Approval
📌 概要
Bayesian Health宣布其获FDA批准的AI脓毒症监测设备获得美国医保新技术附加支付（NTAP）资格，自2026年10月1日起，医院使用该持续监测设备处理符合条件的住院病例可获额外医保支付。公司称这是疑似前脓毒症预警类设备的首条报销通道。
⚡ 关键要点
- ▸Bayesian Health的AI脓毒症监测设备获Medicare新技术附加支付批准
- ▸2026年10月1日起医院可对符合条件的住院病例获得额外支付
- ▸该公司称此为首条针对疑似前脓毒症设备的报销通道
Bayesian Health announced on September 2, 2026 that its FDA-cleared sepsis flagging device has been approved for a New Technology Add-on Payment, the Medicare mechanism that temporarily reimburses hospitals for using qualifying new technologies. Beginning October 1, 2026, hospitals using the continuous AI sepsis monitor can receive additional Medicare payment for eligible inpatient cases. The company described the approval as the first reimbursement pathway of its kind for pre-suspicion sepsis…